From the PharmaTimes via the PharmaGossip blog, here we have a recap of the 'Genzyme manufacturing woes' saga by key dates. The latest this month is the revelation that an additional $6.5 M inventory write off had to be taken and that the manufacturing fixes mandated by the FDA are likely going to take more than 4 years to complete.
How this might affect the Sanofi purchase offer is anyone's guess? It is likely to make it more improbable that Sanofi would try anything hostile if negotiations don't go well as the ongoing manufacturing issues are a bit of a black box to an outside bidder. Read the comments section for more info from other sources.
Posted by Bruce Lehr August 16th 2010.